Bergen, Norway, 17 November 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, announces its results for the third quarter of 2020.

A presentation and live webcast by BerGenBio's senior management will take place
at 10.00 am CET today, please see below for details.

Operational Highlights - third quarter of 2020 (including post-period end)

Oncology

  · Primary endpoint met in BERGAMO Phase II Trial investigating bemcentinib in
patients with High Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid
Leukaemia (AML)
    · The multicenter Phase II study evaluated the safety and efficacy of
bemcentinib monotherapy in 45 patients with HR-MDS or AML who had relapsed
following multiple rounds of prior treatment with hypomethylating agents (HMAs)
    · The primary endpoint overall response rate (CR, Cri, PR or SD) assessed
after 4 treatment cycles was met,
    · Data from this trial will be presented at ASH in December 2020.

  · First patient dosed in investigator led study assessing bemcentinib in
recurrent glioblastoma (GBM)
    · Increased expression of the receptor tyrosine kinase AXL is significantly
correlated with poor prognosis in GBM patients and preclinical data has
suggested that bemcentinib may be a promising therapeutic agent for GBM
    · The study will enroll up to 20 recurrent GMB patients, at up to 15 sites
in the US

  · First patient dosed in MiST3 trial assessing bemcentinib in relapsed
malignant pleural mesothelioma patients
    · The investigator led study, sponsored by the University of Leicester, is
funded by the British Lung Foundation, and is in collaboration with MERCK